- Trials with a EudraCT protocol (46)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
46 result(s) found for: Perimetry.
Displaying page 1 of 3.
EudraCT Number: 2022-004142-35 | Sponsor Protocol Number: ABSALON | Start Date*: 2023-04-18 | |||||||||||
Sponsor Name:Department of Ophthalmology, Rigshospitalet | |||||||||||||
Full Title: Additive Benefits of Semaglutide for open-AngLe glaucoma – an Opportunity for Neuroprotection (ABSALON) | |||||||||||||
Medical condition: mild and moderate glaucoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005943-27 | Sponsor Protocol Number: 975 | Start Date*: 2007-06-01 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: Evaluation of the retinal electrofisiological response in patients with compensated GLAUCOMA POAG in treatment with epigallocatechin-gallate Epinerve . | |||||||||||||
Medical condition: glaucoma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002728-19 | Sponsor Protocol Number: PQ-421a-004 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:ProQR Therapeutics IV B.V. | |||||||||||||
Full Title: A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of t... | |||||||||||||
Medical condition: Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) NO (Prematurely Ended) DK (Completed) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003079-31 | Sponsor Protocol Number: QRK207 | Start Date*: 2016-10-20 | |||||||||||
Sponsor Name:Quark Pharmaceuticals Inc. | |||||||||||||
Full Title: A PHASE 2/3, RANDOMIZED, DOUBLE-MASKED, SHAMCONTROLLED TRIAL OF QPI-1007 DELIVERED BY SINGLE OR MULTI-DOSE INTRAVITREAL INJECTION(S) TO SUBJECTS WITH ACUTE NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEU... | |||||||||||||
Medical condition: NAION typically presents as an abrupt, painless monocular vision loss. Visual loss varies widely, ranging from visual field loss only to complete blindness. The neuronal degeneration process in N... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002436-82 | Sponsor Protocol Number: EC11-441 | Start Date*: 2012-12-13 |
Sponsor Name:Isabel Pinilla Lozano | ||
Full Title: Melatonin effects on visual and sleep patterns anomalies in subjects diagnosed with Retinitis Pigmentosa | ||
Medical condition: To evaluate the sleep quality in patients with Retinitis Pigmentosa | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-007853-30 | Sponsor Protocol Number: sNN0031-001 | Start Date*: 2009-01-28 |
Sponsor Name:NeuroNova AB | ||
Full Title: A randomized, double-blind, placebo controlled, safety and tolerability study of intracerebroventricular administration of sNN0031 to patients with idiopathic Parkinson's disease (PD) of moderate s... | ||
Medical condition: Idiopathic Parkinson's disease (PD) of moderate severity (modified Hoehn & Yahr Stage IIb - III) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-002729-74 | Sponsor Protocol Number: PQ-421a-003 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:ProQR Therapeutics IV B.V. | |||||||||||||
Full Title: A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of t... | |||||||||||||
Medical condition: Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) NO (Completed) DK (Completed) NL (Ongoing) IT (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002546-36 | Sponsor Protocol Number: 2018-002546-36 | Start Date*: 2020-03-10 |
Sponsor Name:Oslo University Hospital | ||
Full Title: TENECTEPLASE IN CENTRAL RETINAL ARTERY OCCLUSION STUDY (TenCRAOS): A PROSPECTIVE, RANDOMIZED-CONTROLLED, DOUBLE-DUMMY, DOUBLE-BLIND PHASE 3 MULTI-CENTRE TRIAL OF TNK 0.25 MG/KG + PLACEBO VS. ASA... | ||
Medical condition: Central retinal artery occlusion | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Trial now transitioned) LT (Completed) FI (Trial now transitioned) DK (Trial now transitioned) IE (Trial now transitioned) BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2004-005197-23 | Sponsor Protocol Number: 1/1 | Start Date*: 2005-10-06 |
Sponsor Name:Klinik und Poliklinik für Augenheilkunde der Universität Regensburg | ||
Full Title: Funktionelle Ergebnisse der intravitrealen Injektion von Triamcinolonacetonid im Vergleich zur konventionellen Lasertherapie bei diabetischem Makulaödem. | ||
Medical condition: Patients with diffuse macular edema due to diabetic retinopathy and decrease in visual acuity. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-023111-34 | Sponsor Protocol Number: SG1/001/10 | Start Date*: 2011-07-18 |
Sponsor Name:Oxford BioMedica (UK) Ltd | ||
Full Title: A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected StarGen, Administered to Patients with Stargardt's Macular Degeneration. | ||
Medical condition: Stargardt Macular Dystrophy, also known as fundus flavimaculatus or Stargardt disease. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) NL (Not Authorised) IT (Prematurely Ended) Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2021-000265-33 | Sponsor Protocol Number: 3000LM | Start Date*: 2021-02-25 |
Sponsor Name:The Rotterdam Eye Hospital | ||
Full Title: Prospective study on safety and efficacy of gene therapy with voretigene neparvovec (Luxturna®) in patients with RPE65-associated inherited retinal degenerations | ||
Medical condition: RPE65-associated inherited retinal degeneration | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000425-31 | Sponsor Protocol Number: MGT010 | Start Date*: 2018-08-30 | |||||||||||
Sponsor Name:MeiraGTx UK II Ltd | |||||||||||||
Full Title: Long term follow-up study of participants following an open label, multicentre, Phase I/II dose escalation trial of a recombinant adeno-associated virus vector (AAV2/5-hRKp.RPGR) for gene therapy o... | |||||||||||||
Medical condition: X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001171-36 | Sponsor Protocol Number: TG-MV-001 | Start Date*: 2005-05-13 |
Sponsor Name:ThromboGenics Ltd. | ||
Full Title: A Dose-Escalation Clinical Trial of Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy for Vitreomacular Traction Maculopathy | ||
Medical condition: Vitreomacular Traction Maculopathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-002666-47 | Sponsor Protocol Number: SOAP1 | Start Date*: 2017-11-02 | |||||||||||
Sponsor Name:Dpt. of Ophthalmology, Rigshospitalet-Glostrup | |||||||||||||
Full Title: Effect of drop-less surgery compared to topical NSAID alone and combination of steroid and NSAID on central macular thickness after cataract surgery, a randomized controlled trial | |||||||||||||
Medical condition: Postoperative cystoid macular edema following cataract surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005228-10 | Sponsor Protocol Number: TG-MV-008 | Start Date*: 2008-10-03 | |||||||||||
Sponsor Name:ThromboGenics NV | |||||||||||||
Full Title: An Open Label, Single Center Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion | |||||||||||||
Medical condition: Focal vitreomacular adhesion | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005592-14 | Sponsor Protocol Number: 26 | Start Date*: 2006-07-27 |
Sponsor Name:IFSgGmbH, Institute for clinical research | ||
Full Title: Double blind, placebo-controlled study to determine the safety and efficacy of erythropoietin as an add-on therapy to methylprednisolone in subjects with acute autoimmune optic neuritis (VISION PRO... | ||
Medical condition: Multiple sclerosis (MS) is a chronic disease of the central nervous system.Optic neuritis represents one of the most common and frequently the first clinical manifestation of MS. Optic neuritis is ... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-002653-29 | Sponsor Protocol Number: NOMA | Start Date*: 2020-03-16 |
Sponsor Name:FUNDACION JIMENEZ DIAZ HEALTH RESEARCH INSTITUTE | ||
Full Title: Multicenter, randomized, dose-finding, parallel, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of intramuscular administration of allogeneic mesenchymal cells de... | ||
Medical condition: Critical ischemia of lower limbs in diabetic patients | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001493-28 | Sponsor Protocol Number: OPA1 | Start Date*: 2020-09-24 | |||||||||||
Sponsor Name:Medizinische Universität Graz, Univ.-Augenklinik | |||||||||||||
Full Title: Raxone® treatment for patients with dominant optic atrophy due to OPA1 gene mutation | |||||||||||||
Medical condition: Autosomal dominant optic atrophy (ADOA) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001874-32 | Sponsor Protocol Number: RDC-CNGA3-01 | Start Date*: 2015-09-09 | |||||||||||
Sponsor Name:Universitätsklinikum Tübingen | |||||||||||||
Full Title: Safety and efficacy of a bilateral single subretinal injection of rAAV.hCNGA3 in adult and minor patients with CNGA3-linked achromatopsia investigated in a randomized, wait list controlled, observe... | |||||||||||||
Medical condition: CNGA3-linked achromatopsia | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001990-95 | Sponsor Protocol Number: LTS13588-(SG1/002/11) | Start Date*: 2012-11-09 | |||||||||||
Sponsor Name:sanofi-aventis recherche et développement | |||||||||||||
Full Title: An Open Label Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients with Stargardt’s Macular Degeneration | |||||||||||||
Medical condition: Stargardt Macular Dystrophy, also known as fundus flavimaculatus or Stargardt disease. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
